nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Brimonidine—AOX1—prostate cancer	0.0138	0.599	CrCbGaD
Apraclonidine—Clonidine—SLC22A3—prostate cancer	0.00314	0.136	CrCbGaD
Apraclonidine—Clonidine—SLC22A1—prostate cancer	0.00225	0.0978	CrCbGaD
Apraclonidine—Clonidine—CYP3A5—prostate cancer	0.00182	0.0789	CrCbGaD
Apraclonidine—Clonidine—CYP1A1—prostate cancer	0.00123	0.0535	CrCbGaD
Apraclonidine—Clonidine—CYP3A4—prostate cancer	0.000786	0.0342	CrCbGaD
Apraclonidine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000465	0.000594	CcSEcCtD
Apraclonidine—Erythema—Capecitabine—prostate cancer	0.000463	0.000591	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—prostate cancer	0.000463	0.000591	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000462	0.000589	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—prostate cancer	0.000456	0.000582	CcSEcCtD
Apraclonidine—Nausea—Goserelin—prostate cancer	0.000454	0.00058	CcSEcCtD
Apraclonidine—Dysgeusia—Capecitabine—prostate cancer	0.000454	0.000579	CcSEcCtD
Apraclonidine—Nausea—Conjugated Estrogens—prostate cancer	0.00045	0.000574	CcSEcCtD
Apraclonidine—Hypersensitivity—Estradiol—prostate cancer	0.000447	0.00057	CcSEcCtD
Apraclonidine—Abdominal pain—Mitoxantrone—prostate cancer	0.000447	0.00057	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—prostate cancer	0.000443	0.000566	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—prostate cancer	0.000443	0.000565	CcSEcCtD
Apraclonidine—Vision blurred—Capecitabine—prostate cancer	0.000437	0.000557	CcSEcCtD
Apraclonidine—Asthenia—Estradiol—prostate cancer	0.000435	0.000555	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—prostate cancer	0.00043	0.000549	CcSEcCtD
Apraclonidine—Ill-defined disorder—Capecitabine—prostate cancer	0.00043	0.000548	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—prostate cancer	0.000429	0.000547	CcSEcCtD
Apraclonidine—Pruritus—Estradiol—prostate cancer	0.000429	0.000547	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—prostate cancer	0.000429	0.000547	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—prostate cancer	0.000423	0.00054	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—prostate cancer	0.000423	0.000539	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—prostate cancer	0.000422	0.000538	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—prostate cancer	0.000419	0.000534	CcSEcCtD
Apraclonidine—Malaise—Capecitabine—prostate cancer	0.000418	0.000533	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—prostate cancer	0.000418	0.000533	CcSEcCtD
Apraclonidine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000416	0.000531	CcSEcCtD
Apraclonidine—Syncope—Capecitabine—prostate cancer	0.000415	0.00053	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—prostate cancer	0.000415	0.00053	CcSEcCtD
Apraclonidine—Diarrhoea—Estradiol—prostate cancer	0.000415	0.000529	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—prostate cancer	0.000413	0.000527	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—prostate cancer	0.000413	0.000527	CcSEcCtD
Apraclonidine—Erythema—Prednisone—prostate cancer	0.000413	0.000526	CcSEcCtD
Apraclonidine—Palpitations—Capecitabine—prostate cancer	0.000409	0.000522	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—prostate cancer	0.000407	0.00052	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—prostate cancer	0.000407	0.00052	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000406	0.000518	CcSEcCtD
Apraclonidine—Asthenia—Mitoxantrone—prostate cancer	0.000405	0.000517	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—prostate cancer	0.000405	0.000517	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000405	0.000516	CcSEcCtD
Apraclonidine—Constipation—Etoposide—prostate cancer	0.000402	0.000513	CcSEcCtD
Apraclonidine—Pain—Etoposide—prostate cancer	0.000402	0.000513	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—prostate cancer	0.000401	0.000512	CcSEcCtD
Apraclonidine—Dizziness—Estradiol—prostate cancer	0.000401	0.000511	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—prostate cancer	0.000398	0.000508	CcSEcCtD
Apraclonidine—Myalgia—Capecitabine—prostate cancer	0.000394	0.000503	CcSEcCtD
Apraclonidine—Chest pain—Capecitabine—prostate cancer	0.000394	0.000503	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000392	0.0005	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—prostate cancer	0.00039	0.000498	CcSEcCtD
Apraclonidine—Discomfort—Capecitabine—prostate cancer	0.00039	0.000497	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—prostate cancer	0.000389	0.000496	CcSEcCtD
Apraclonidine—Infection—Docetaxel—prostate cancer	0.000388	0.000495	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—prostate cancer	0.000387	0.000494	CcSEcCtD
Apraclonidine—Diarrhoea—Mitoxantrone—prostate cancer	0.000386	0.000493	CcSEcCtD
Apraclonidine—Dry mouth—Capecitabine—prostate cancer	0.000386	0.000492	CcSEcCtD
Apraclonidine—Vomiting—Estradiol—prostate cancer	0.000385	0.000492	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—prostate cancer	0.000384	0.00049	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—prostate cancer	0.000383	0.000489	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—prostate cancer	0.000383	0.000488	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—prostate cancer	0.000382	0.000487	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—prostate cancer	0.000382	0.000487	CcSEcCtD
Apraclonidine—Dermatitis—Estradiol—prostate cancer	0.000382	0.000487	CcSEcCtD
Apraclonidine—Headache—Estradiol—prostate cancer	0.00038	0.000485	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—prostate cancer	0.000379	0.000484	CcSEcCtD
Apraclonidine—Oedema—Capecitabine—prostate cancer	0.000378	0.000482	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—prostate cancer	0.000377	0.000481	CcSEcCtD
Apraclonidine—Infection—Capecitabine—prostate cancer	0.000376	0.000479	CcSEcCtD
Apraclonidine—Malaise—Prednisone—prostate cancer	0.000372	0.000475	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—prostate cancer	0.000372	0.000474	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—prostate cancer	0.000371	0.000474	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—prostate cancer	0.000371	0.000474	CcSEcCtD
Apraclonidine—Nervous system disorder—Capecitabine—prostate cancer	0.000371	0.000473	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—prostate cancer	0.000371	0.000473	CcSEcCtD
Apraclonidine—Syncope—Prednisone—prostate cancer	0.00037	0.000472	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—prostate cancer	0.000368	0.000469	CcSEcCtD
Apraclonidine—Skin disorder—Capecitabine—prostate cancer	0.000367	0.000469	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—prostate cancer	0.000365	0.000466	CcSEcCtD
Apraclonidine—Nausea—Estradiol—prostate cancer	0.00036	0.000459	CcSEcCtD
Apraclonidine—Vomiting—Mitoxantrone—prostate cancer	0.000359	0.000458	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—prostate cancer	0.000357	0.000456	CcSEcCtD
Apraclonidine—Dermatitis—Mitoxantrone—prostate cancer	0.000356	0.000454	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000356	0.000454	CcSEcCtD
Apraclonidine—Headache—Mitoxantrone—prostate cancer	0.000354	0.000451	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—prostate cancer	0.000353	0.000451	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—prostate cancer	0.000351	0.000448	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—prostate cancer	0.000351	0.000447	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—prostate cancer	0.000349	0.000446	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000349	0.000445	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—prostate cancer	0.000348	0.000444	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—prostate cancer	0.000347	0.000443	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—prostate cancer	0.000347	0.000443	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—prostate cancer	0.000346	0.000442	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—prostate cancer	0.000346	0.000442	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000344	0.000439	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—prostate cancer	0.000344	0.000439	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—prostate cancer	0.000343	0.000438	CcSEcCtD
Apraclonidine—Insomnia—Capecitabine—prostate cancer	0.000342	0.000436	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—prostate cancer	0.00034	0.000434	CcSEcCtD
Apraclonidine—Paraesthesia—Capecitabine—prostate cancer	0.000339	0.000433	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—prostate cancer	0.000338	0.000431	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000337	0.00043	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—prostate cancer	0.000337	0.00043	CcSEcCtD
Apraclonidine—Dyspnoea—Capecitabine—prostate cancer	0.000337	0.00043	CcSEcCtD
Apraclonidine—Oedema—Prednisone—prostate cancer	0.000337	0.00043	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—prostate cancer	0.000337	0.00043	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—prostate cancer	0.000336	0.000429	CcSEcCtD
Apraclonidine—Nausea—Mitoxantrone—prostate cancer	0.000336	0.000428	CcSEcCtD
Apraclonidine—Infection—Prednisone—prostate cancer	0.000335	0.000427	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—prostate cancer	0.000334	0.000426	CcSEcCtD
Apraclonidine—Pain—Docetaxel—prostate cancer	0.000334	0.000426	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—prostate cancer	0.000334	0.000426	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—prostate cancer	0.000332	0.000424	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—prostate cancer	0.000331	0.000423	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—prostate cancer	0.000331	0.000422	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—prostate cancer	0.00033	0.000421	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—prostate cancer	0.000327	0.000417	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000326	0.000416	CcSEcCtD
Apraclonidine—Fatigue—Capecitabine—prostate cancer	0.000326	0.000416	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—prostate cancer	0.000325	0.000414	CcSEcCtD
Apraclonidine—Constipation—Capecitabine—prostate cancer	0.000323	0.000412	CcSEcCtD
Apraclonidine—Pain—Capecitabine—prostate cancer	0.000323	0.000412	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—prostate cancer	0.000323	0.000412	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—prostate cancer	0.000322	0.000411	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—prostate cancer	0.000321	0.00041	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—prostate cancer	0.000321	0.000409	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000319	0.000407	CcSEcCtD
Apraclonidine—Tension—Epirubicin—prostate cancer	0.000317	0.000404	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—prostate cancer	0.000316	0.000403	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—prostate cancer	0.000313	0.0004	CcSEcCtD
Apraclonidine—Feeling abnormal—Capecitabine—prostate cancer	0.000312	0.000397	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—prostate cancer	0.000311	0.000397	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—prostate cancer	0.000311	0.000396	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000309	0.000394	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000309	0.000394	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—prostate cancer	0.000309	0.000394	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000307	0.000391	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—prostate cancer	0.000306	0.000391	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—prostate cancer	0.000305	0.000389	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—prostate cancer	0.000304	0.000388	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—prostate cancer	0.000302	0.000386	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—prostate cancer	0.000301	0.000383	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—prostate cancer	0.000299	0.000382	CcSEcCtD
Apraclonidine—Abdominal pain—Capecitabine—prostate cancer	0.000299	0.000381	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—prostate cancer	0.000299	0.000381	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—prostate cancer	0.000299	0.000381	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—prostate cancer	0.000296	0.000378	CcSEcCtD
Apraclonidine—Headache—Etoposide—prostate cancer	0.000294	0.000376	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—prostate cancer	0.000293	0.000374	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—prostate cancer	0.000292	0.000373	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—prostate cancer	0.000291	0.000371	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—prostate cancer	0.00029	0.00037	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—prostate cancer	0.00029	0.00037	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—prostate cancer	0.000289	0.000369	CcSEcCtD
Apraclonidine—Constipation—Prednisone—prostate cancer	0.000288	0.000367	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—prostate cancer	0.000288	0.000367	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—prostate cancer	0.000285	0.000364	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—prostate cancer	0.000281	0.000359	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—prostate cancer	0.00028	0.000357	CcSEcCtD
Apraclonidine—Nausea—Etoposide—prostate cancer	0.000279	0.000356	CcSEcCtD
Apraclonidine—Hypersensitivity—Capecitabine—prostate cancer	0.000279	0.000355	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—prostate cancer	0.000278	0.000354	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—prostate cancer	0.000277	0.000353	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—prostate cancer	0.000276	0.000352	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—prostate cancer	0.000275	0.000351	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—prostate cancer	0.000275	0.000351	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—prostate cancer	0.000275	0.000351	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000273	0.000348	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—prostate cancer	0.000271	0.000346	CcSEcCtD
Apraclonidine—Asthenia—Capecitabine—prostate cancer	0.000271	0.000346	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—prostate cancer	0.000269	0.000344	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—prostate cancer	0.000269	0.000343	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—prostate cancer	0.000268	0.000342	CcSEcCtD
Apraclonidine—Pruritus—Capecitabine—prostate cancer	0.000267	0.000341	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—prostate cancer	0.000267	0.000341	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—prostate cancer	0.000266	0.00034	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—prostate cancer	0.000264	0.000337	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—prostate cancer	0.000263	0.000336	CcSEcCtD
Apraclonidine—Infection—Epirubicin—prostate cancer	0.000262	0.000334	CcSEcCtD
Apraclonidine—Diarrhoea—Capecitabine—prostate cancer	0.000259	0.00033	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—prostate cancer	0.000258	0.00033	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—prostate cancer	0.000258	0.000329	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—prostate cancer	0.000256	0.000326	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—prostate cancer	0.000254	0.000324	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—prostate cancer	0.000254	0.000324	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000252	0.000322	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—prostate cancer	0.000251	0.00032	CcSEcCtD
Apraclonidine—Dizziness—Capecitabine—prostate cancer	0.00025	0.000319	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—prostate cancer	0.000249	0.000317	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—prostate cancer	0.000248	0.000317	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—prostate cancer	0.000248	0.000317	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—prostate cancer	0.000246	0.000314	CcSEcCtD
Apraclonidine—Headache—Docetaxel—prostate cancer	0.000245	0.000312	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—prostate cancer	0.000244	0.000311	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—prostate cancer	0.000242	0.000309	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—prostate cancer	0.000242	0.000308	CcSEcCtD
Apraclonidine—Vomiting—Capecitabine—prostate cancer	0.00024	0.000307	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.00024	0.000306	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—prostate cancer	0.000239	0.000305	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—prostate cancer	0.000238	0.000304	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—prostate cancer	0.000238	0.000304	CcSEcCtD
Apraclonidine—Dermatitis—Capecitabine—prostate cancer	0.000238	0.000304	CcSEcCtD
Apraclonidine—Headache—Capecitabine—prostate cancer	0.000237	0.000302	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—prostate cancer	0.000237	0.000302	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—prostate cancer	0.000237	0.000302	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—prostate cancer	0.000235	0.0003	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—prostate cancer	0.000234	0.000299	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—prostate cancer	0.000232	0.000296	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—prostate cancer	0.00023	0.000294	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000227	0.00029	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—prostate cancer	0.000227	0.00029	CcSEcCtD
Apraclonidine—Pain—Epirubicin—prostate cancer	0.000225	0.000287	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—prostate cancer	0.000225	0.000287	CcSEcCtD
Apraclonidine—Nausea—Capecitabine—prostate cancer	0.000225	0.000286	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—prostate cancer	0.000223	0.000284	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000222	0.000283	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—prostate cancer	0.00022	0.000281	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—prostate cancer	0.000219	0.000279	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—prostate cancer	0.000217	0.000277	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—prostate cancer	0.000217	0.000277	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—prostate cancer	0.000217	0.000276	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000215	0.000275	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—prostate cancer	0.000214	0.000273	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—prostate cancer	0.000212	0.000271	CcSEcCtD
Apraclonidine—Headache—Prednisone—prostate cancer	0.000211	0.000269	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.00021	0.000268	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—prostate cancer	0.00021	0.000268	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—prostate cancer	0.000208	0.000266	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—prostate cancer	0.000208	0.000266	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—prostate cancer	0.000208	0.000266	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—prostate cancer	0.000201	0.000256	CcSEcCtD
Apraclonidine—Nausea—Prednisone—prostate cancer	0.0002	0.000255	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000199	0.000254	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—prostate cancer	0.000194	0.000248	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—prostate cancer	0.000193	0.000246	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—prostate cancer	0.000189	0.000241	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—prostate cancer	0.000186	0.000238	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—prostate cancer	0.00018	0.00023	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—prostate cancer	0.00018	0.000229	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—prostate cancer	0.000175	0.000223	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—prostate cancer	0.000174	0.000222	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—prostate cancer	0.000172	0.00022	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—prostate cancer	0.000167	0.000214	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—prostate cancer	0.000167	0.000213	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—prostate cancer	0.000166	0.000212	CcSEcCtD
Apraclonidine—Headache—Epirubicin—prostate cancer	0.000165	0.000211	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—prostate cancer	0.000161	0.000206	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—prostate cancer	0.000156	0.0002	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—prostate cancer	0.000155	0.000198	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—prostate cancer	0.000154	0.000196	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—prostate cancer	0.000153	0.000195	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—prostate cancer	0.000145	0.000185	CcSEcCtD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—prostate cancer	2.9e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	2.88e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	2.87e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—prostate cancer	2.85e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARA—prostate cancer	2.84e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	2.84e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—prostate cancer	2.84e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—prostate cancer	2.84e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—prostate cancer	2.82e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1R—prostate cancer	2.81e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—prostate cancer	2.81e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	2.8e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—prostate cancer	2.8e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—JAK2—prostate cancer	2.78e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CREBBP—prostate cancer	2.78e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—prostate cancer	2.78e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BAD—prostate cancer	2.77e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—prostate cancer	2.75e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	2.73e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—prostate cancer	2.72e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—prostate cancer	2.71e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	2.71e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	2.71e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—prostate cancer	2.69e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APC—prostate cancer	2.68e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—prostate cancer	2.68e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—prostate cancer	2.67e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—prostate cancer	2.67e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFRB—prostate cancer	2.67e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGF—prostate cancer	2.65e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS1—prostate cancer	2.65e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—prostate cancer	2.65e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—prostate cancer	2.64e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—prostate cancer	2.64e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—prostate cancer	2.61e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—prostate cancer	2.6e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ITGB3—prostate cancer	2.6e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BAD—prostate cancer	2.59e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GSK3B—prostate cancer	2.58e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—prostate cancer	2.54e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—prostate cancer	2.54e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB3—prostate cancer	2.52e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR2—prostate cancer	2.52e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APC—prostate cancer	2.51e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—prostate cancer	2.51e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—prostate cancer	2.49e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	2.49e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	2.49e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGF—prostate cancer	2.48e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS1—prostate cancer	2.48e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—prostate cancer	2.46e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	2.45e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—prostate cancer	2.44e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—prostate cancer	2.43e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—prostate cancer	2.43e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—prostate cancer	2.42e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—prostate cancer	2.41e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	2.41e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—prostate cancer	2.38e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	2.38e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—prostate cancer	2.37e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	2.36e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	2.34e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	2.33e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	2.32e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—prostate cancer	2.32e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	2.31e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	2.31e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—prostate cancer	2.31e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—prostate cancer	2.3e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—prostate cancer	2.3e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—prostate cancer	2.29e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	2.28e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—prostate cancer	2.28e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BAD—prostate cancer	2.26e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—prostate cancer	2.26e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CREBBP—prostate cancer	2.26e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—prostate cancer	2.26e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	2.24e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—prostate cancer	2.23e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	2.22e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—prostate cancer	2.21e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	2.2e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APC—prostate cancer	2.19e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	2.19e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	2.18e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	2.18e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGF—prostate cancer	2.17e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS1—prostate cancer	2.17e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	2.17e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	2.16e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	2.15e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—prostate cancer	2.14e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	2.12e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	2.11e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	2.11e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	2.1e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BAD—prostate cancer	2.1e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	2.08e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	2.08e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—prostate cancer	2.08e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	2.06e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APC—prostate cancer	2.04e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	2.04e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	2.03e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	2.02e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—prostate cancer	2.02e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	2.01e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGF—prostate cancer	2.01e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—prostate cancer	2.01e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	2e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—prostate cancer	1.99e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	1.98e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	1.98e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	1.97e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	1.95e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	1.95e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.94e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	1.93e-05	9.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—prostate cancer	1.93e-05	9.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.93e-05	9.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	1.92e-05	9.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	1.91e-05	9.89e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.91e-05	9.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.91e-05	9.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—prostate cancer	1.89e-05	9.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	1.89e-05	9.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—prostate cancer	1.89e-05	9.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	1.89e-05	9.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.89e-05	9.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	1.88e-05	9.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—prostate cancer	1.87e-05	9.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	1.86e-05	9.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	1.86e-05	9.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—prostate cancer	1.85e-05	9.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	1.85e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.85e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	1.84e-05	9.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	1.82e-05	9.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.82e-05	9.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	1.8e-05	9.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.8e-05	9.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.79e-05	9.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	1.79e-05	9.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	1.78e-05	9.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	1.78e-05	9.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	1.78e-05	9.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.77e-05	9.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.77e-05	9.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.77e-05	9.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	1.77e-05	9.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—prostate cancer	1.76e-05	9.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	1.76e-05	9.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	1.75e-05	9.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	1.73e-05	8.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.73e-05	8.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.73e-05	8.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	1.72e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.71e-05	8.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	1.7e-05	8.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.7e-05	8.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—prostate cancer	1.7e-05	8.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.69e-05	8.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.68e-05	8.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	1.67e-05	8.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	1.66e-05	8.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	1.66e-05	8.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—prostate cancer	1.65e-05	8.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.64e-05	8.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	1.62e-05	8.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.61e-05	8.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—prostate cancer	1.61e-05	8.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.61e-05	8.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	1.61e-05	8.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.6e-05	8.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	1.59e-05	8.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—prostate cancer	1.58e-05	8.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.58e-05	8.19e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.58e-05	8.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.56e-05	8.08e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.56e-05	8.07e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.54e-05	8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.54e-05	7.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—prostate cancer	1.54e-05	7.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—prostate cancer	1.54e-05	7.96e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.53e-05	7.95e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.5e-05	7.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.49e-05	7.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	1.48e-05	7.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.48e-05	7.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.47e-05	7.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.46e-05	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.46e-05	7.56e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.45e-05	7.53e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.45e-05	7.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.45e-05	7.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.44e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.44e-05	7.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.43e-05	7.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.43e-05	7.38e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.42e-05	7.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—prostate cancer	1.4e-05	7.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.4e-05	7.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.38e-05	7.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.38e-05	7.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—prostate cancer	1.38e-05	7.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	1.38e-05	7.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	1.36e-05	7.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.36e-05	7.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.35e-05	7e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	1.35e-05	6.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.35e-05	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.35e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.32e-05	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.31e-05	6.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.3e-05	6.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.29e-05	6.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	1.27e-05	6.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	1.25e-05	6.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.25e-05	6.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.22e-05	6.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—prostate cancer	1.21e-05	6.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.21e-05	6.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.21e-05	6.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.2e-05	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.18e-05	6.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	1.17e-05	6.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—prostate cancer	1.14e-05	5.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.14e-05	5.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—prostate cancer	1.13e-05	5.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.12e-05	5.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.12e-05	5.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.11e-05	5.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.11e-05	5.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.1e-05	5.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.04e-05	5.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.04e-05	5.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.02e-05	5.3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.02e-05	5.3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—prostate cancer	9.91e-06	5.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	9.57e-06	4.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	9.51e-06	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—prostate cancer	9.29e-06	4.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—prostate cancer	9.2e-06	4.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—prostate cancer	9.07e-06	4.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—prostate cancer	8.42e-06	4.36e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	8.36e-06	4.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	7.77e-06	4.02e-05	CbGpPWpGaD
